Development of an adverse outcome pathway for chemically induced hepatocellular carcinoma: case study of AFB1, a human carcinogen with a mutagenic mode of action

References

• Aguilar F, Hussain SP, Cerutti P. 1993. Aflatoxin B1 induces the transversion of G->T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc Natl Acad Sci USA. 90:8586–8590.
   PubMed Web of Science ®Google Scholar
• Alekseyev YO, Hamm ML, Essignmann JM. 2004. Aflatoxin B1 formamidopyrimidine adducts are preferentially repaired by the nucleotide excision repair pathway in vivo. Carcinogenesis. 25:1045–1051.
   PubMed Web of Science ®Google Scholar
• Angsubhakorn S, Pradermwong A, Phanwichien K, Nguansangiam S. 2002. Promotion of aflatoxin B1-induced hepatocarcinogenesis by dichlorodiphenyl trichloroethane (DDT). Southeast Asian J Trop Med Public Health. 33:613–623.
   PubMedGoogle Scholar
• Ankley GT, Bennett RS, Erickson RJ, Hoff DJ, Hornung MW, Johnson RD, Mount DR, Nichols JW, Russom CL, Schmieder PK, et al. 2010. Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment. Environ Toxicol Chem. 29:730–741.
   PubMed Web of Science ®Google Scholar
• Appleton BS, Goetchius MP, Campbell TC. 1982. Linear dose-response curve for the hepatic macromolecular binding of aflatoxin B1 in rats at very low exposures. Cancer Res. 42:3659–3662.
   PubMed Web of Science ®Google Scholar
• Asplin FD, Carnaghan RBA. 1961. The toxicity of certain groundnut meals for poultry with special reference to their effect on ducklings and chickens. Vet Rec. 73:1215–1219.
   Google Scholar
• Autrup H, Jorgensen EC, Jensen O. 1996. Aflatoxin B1 induced lacI mutation in liver and kidney of transgenic mice C57BL/6N: effect of phorone. Mutagenesis. 11:69–73.
   PubMed Web of Science ®Google Scholar
• Bailey EA, Iyer RS, Stone MP, Harris TM, Essigmann JM. 1996. Mutational properties of the primary aflatoxin B1-DNA adduct. Proc Natl Acad Sci USA. 93:1535–1539.
   PubMed Web of Science ®Google Scholar
• Bal-Price A, Lein PJ, Keil KP, Sethi S, Shafer T, Barenys M, Fritsche E, Sachana M, Meek ME. 2017. Developing and applying the adverse outcome pathway concept for understanding and predicting neurotoxicity. Neurotoxicology. 59:240–255.
   PubMed Web of Science ®Google Scholar
• Banarjee S, Brown KL, Egli M, Stone MP. 2011. Bypass of aflatoxin B1 adducts by the sulfolobus solfataricus DNA polymerase IV. J Am Chem Soc. 133:12556–12568.
   PubMed Web of Science ®Google Scholar
• Bannasch P, Benner U, Enzmann H, Hacker HJ. 1985. Tigroid cell foci and neoplastic nodules in the liver of rats treated with a single dose of aflatoxin B1. Carcinogenesis. 6:1641–1648.
   PubMed Web of Science ®Google Scholar
• Bannasch P, Khoshkhou NI, Hacker HJ, Radaeva S, Mrozek M, Zillmann U, Kopp-Schneider A, Haberkorn U, Eglas M, Tolle T. 1995. Synergistic heptaocarcinogenic effect of hepadnaviral infection and dietary aflatoxin B1 woodchucks. Cancer Res. 55:3318–3330.
   PubMed Web of Science ®Google Scholar
• Bechtel DH. 1989. Molecular dosimetry of hepatic aflatoxin B1-DNA adducts: linear correlation with hepatic cancer risk. Regul Toxicol Pharmacol. 10:74–81.
   PubMed Web of Science ®Google Scholar
• Becker RA, Ankley GT, Edwards SW, Kennedy SW, Linkov I, Meek B, Sachana M, Segner H, Van Der Burg B, Villeneuve DL, et al. 2015a. Increasing scientific confidence in adverse outcome pathways: application of tailored Bradford Hill considerations for evaluating weight of evidence. Regul Toxicol Pharmacol. 72:514–537.
   PubMed Web of Science ®Google Scholar
• Becker RA, Patelwicz G, Simon TW, Rowlands JC, Budinsky RA. 2015b. The adverse outcome pathway for rodent liver tumor promotion by sustained activation of the aryl hydrocarbon receptor. Regul Toxicol Pharmacol. 73:172–190.
   PubMed Web of Science ®Google Scholar
• Bedard LL, Massey TE. 2006. Aflatoxin B1-induced DNA damage and its repair. Cancer Lett. 241:174–183.
   PubMed Web of Science ®Google Scholar
• Bedard LL, Alessi M, Davey S, Massey TE. 2005. Susceptibility to aflatoxin B1-induced carcinogenesis correlates with tissue-specific differences in DNA repair activity in mouse and in rat. Cancer Res. 65:1265–1270.
   PubMed Web of Science ®Google Scholar
• Beer DG, Pitot HC. 1987. Biological markers characterizing the development of preneoplastic and neoplastic lesions in rodent liver. Arch Toxicol Suppl. 10:68–80.
   PubMedGoogle Scholar
• Besaratinia A, Kim S, Hainaut P, Pfeifer GP. 2009. In vitro recapitulating of TP53 mutagenesis in hepatocellular carcinoma associated with dietary aflatoxin B1 exposure. Gastroenterology. 137:1127–1137.
   PubMed Web of Science ®Google Scholar
• Boysen G, Pachkowski BF, Nakamura J, Swenberg JA. 2009. The formation and biological significance of N7-guanine adducts. Mutat Res. 678:76–94.
   PubMed Web of Science ®Google Scholar
• Bressac B, Kew M, Wands J, Ozturk M. 1991. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature. 350:429–431.
   PubMed Web of Science ®Google Scholar
• Brown JA, Pack LR, Sanman LE, Suo Z. 2011. Efficiency and fidelity of human DNA polymerases λ and β during gap-filling DNA synthesis. DNA Repair (Amst). 10:24–33.
   PubMed Web of Science ®Google Scholar
• Brown KL, Deng JZ, Iyer RS, Iyer LG, Voehler MW, Stone MP, Harris CM, Harris TM. 2006. Unraveling the aflatoxin-FAPY conundrum: structural basis for differential replicative processing of isomeric forms of the formamidopyrimidine-type DNA adduct of aflatoxin B1. J Am Chem Soc. 128:15188–15199.
   PubMed Web of Science ®Google Scholar
• Bryce SM, Avlasevich SL, Bemis JC, Phonethepswath S, Dertinger SD. 2010. Miniaturized flow cytometric in vitro micronucleus assay represents an efficient tool for comprehensively characterizing genotoxicity dose-response relationships. Mutat Res. 703:191–199.
   PubMed Web of Science ®Google Scholar
• Burden N, Sewell F, Andersen ME, Boobis A, Chipman JK, Cronin MTD, Hutchinson TH, Kimber I, Whelan M. 2015. Adverse outcome pathways can drive non-animal approaches for safety assessment. J Appl Toxicol. 35:971–975.
   PubMed Web of Science ®Google Scholar
• Buss P, Caviezel M, Lutz WK. 1990. Linear dose-response relationship for DNA adducts in rat liver from chronic exposure to aflatoxin B1. Carcinogenesis. 11:2133–2135.
   PubMed Web of Science ®Google Scholar
• Caballero F, Meiss R, Gimenez A, Batlle A, Vasquez E. 2004. Immunohistochemical analysis of heme oxygenase-1 in preneoplastic and neoplastic lesions during chemical heptacarcinogenesis. Int J Exp Pathol. 85:213–222.
   PubMed Web of Science ®Google Scholar
• Chakravarti D, Venugopal D, Mailander P. 2008. The role of polycyclic aromatic hydrocarbon-DNA adducts in inducing mutations in mouse skin. Mutat Res. 649:161–178.
   PubMed Web of Science ®Google Scholar
• Chawanthayatham S, Valentine IIIC, Fedeles B, Fox E, Loeb L, Levine S, Slocum S, Wogan G, Croy R, Essigmann J. 2017. Mutational spectra of aflatoxin B1 in vivo establish biomarkers of exposure for human hepatocellular carcinoma. Proc Natl Acad Sci USA. 114:E3101–E3109.
   PubMed Web of Science ®Google Scholar
• Chen T, Heflich RH, Moore MM, Mei N. 2010. Differential mutagenicity of aflatoxin B1 in the liver of neonatal and adult mice. Environ Mol Mutagen. 51:156–163.
   PubMed Web of Science ®Google Scholar
• Chittmittrapap S, Chieochansin T, Chaiteerakij R, Treeprasertuk S, Klaikaew N, Tangkijvanich P, Komolmit P, Poovorawan Y. 2013. Prevalence of aflatoxin induced P53 mutation at codon 249 (R249s) in heptacellular carcinoma patients with and without hepatitis B surface antigen (HBsAg). Asian Pacific J Cancer Prev. 14:7675–7679.
   PubMedGoogle Scholar
• Cohen SM, Arnold LL. 2011. Chemical carcinogenesis. Toxicol Sci. 120(S1): S76–S92.
   Web of Science ®Google Scholar
• Croy RG, Wogan GN. 1981. Temporal patterns of covalent DNA adducts in rat liver after single and multiple doses of aflatoxin B1. Cancer Res. 41:197–203.
   PubMed Web of Science ®Google Scholar
• Croy RG, Essigmann JM, Reinhold VN, Wogan GN. 1978. Identification of the principal aflatoxin B1-DNA adduct formed in vivo in rat liver. Proc Natl Acad Sci USA. 75:1745–1749.
   PubMed Web of Science ®Google Scholar
• Cullen JM, Marion PL, Sherman GJ, Hong X, Newbold JE. 1990. Hepatic neoplasms in aflatoxin B1-treated, congenital duck hepatitis B virus-infected, and virus-free Pekin ducks. Cancer Res. 50:4072–4080.
   PubMed Web of Science ®Google Scholar
• Cupid BC, Lightfoot TJ, Russell D, Grant SJ, Turner PC, Dingley KH, Curtis KD, Leveson SH, Turteltaub KW, Garner RC. 2004. The formation of AFB(1)-macromolecular adducts in rats and humans at dietary levels of exposure. Food Chem Toxicol. 42:559–569.
   PubMed Web of Science ®Google Scholar
• Dang HT, Budhu A, Wang XW. 2014. The origin of cancer stem cells. J Hepatol. 60:1304–1305.
   PubMed Web of Science ®Google Scholar
• de Carvalho FM, de Almeida Pereira T, Gonçalves PL, Jarske RD, Pereira FEL, Luoro ID. 2013. Heptacellular carcinoma and liver cirrhosis TP53 mutation analysis reflects a moderate dietary exposure to aflatoxins in Espírito Santo State, Brazil. Mol Biol Rep. 40:4883–4887.
   PubMed Web of Science ®Google Scholar
• Degen GH, Neumann HG. 1981. Differences in aflatoxin B1-susceptibility of rat and mouse are correlated with the capability in vitro to inactivate aflatoxin B1-epoxide. Carcinogenesis. 2:299–306.
   PubMed Web of Science ®Google Scholar
• Denissenko MF, Koudriakova TB, Smith L, O’Connor TR, Riggs AD, Pfeifer GP. 1998. The p53 codon 249 mutational hotspot in hepatocellular carcinoma is not related to selective formation or persistence of aflatoxin B1 adducts. Oncogene. 17:3007–3014.
   PubMed Web of Science ®Google Scholar
• Dewanji A, Moolgavkar SH, Luebeck EG. 1991. Two-mutation model for carcinogenesis: Joint analysis of premalignant and malignant lesions. Math Biosci. 104:97–109.
   PubMed Web of Science ®Google Scholar
• Dianov GL, Hübscher U. 2013. Mammalian base excision repair: the forgotten archangel. Nucleic Acids Res. 41:3483–3490.
   PubMed Web of Science ®Google Scholar
• Doak SH, Jenkins GLS, Johnson GE, Quick E, Parry EM, Parry JM. 2007. Mechanistic influences for mutation induction curves after exposure to DNA-reactive carcinogens. Cancer Res. 67:3904–3911.
   PubMed Web of Science ®Google Scholar
• Dobo KL, Fiedler RD, Gunther WC, Thiffeault CJ, Cammerer Z, Coffing SL, Shutsky T, Schuler M. 2011. Defining EMS ad ENU dose-response relationships using the Pig-a mutation essay in rats. Mutat Res. 725:13–21.
   PubMed Web of Science ®Google Scholar
• Dragan YP, Hully J, Crow R, Mass M, Pitot HC. 1994. Incorporation of bromodeoxyuridine in glutathione S-transferase-positive hepatocytes during rat multistage hepatocarcinogenesis. Carcinogenesis. 15:1939–1947.
   PubMed Web of Science ®Google Scholar
• Dragan YP, Hully J, Baker K, Crow R, Mass MJ, Pitot HC. 1995. Comparison of experimental and theoretical parameters of the moolgavkar-venzon-knudson incidence function for the stages of initiation and promotion in rat hepatocarcinogenesis. Toxicology. 102:161–175.
   PubMed Web of Science ®Google Scholar
• Dragan YP, Campbell HA, Xu XH, Pitot HC. 1997. Quantitative stereological studies of a “'selection' protocol of hepatocarcinogenesis following initiation in neonatal male and female rats”. Carcinogenesis. 18:149–158.
   PubMed Web of Science ®Google Scholar
• Dycaico MJJ, Stuart GRR, Tobal GMM, de Boer JGG, Glickman BWW, Provost GSS. 1996. Species-specific differences in hepatic mutant frequency and mutational spectrum among lambda/lacI transgenic rats and mice following exposure to aflatoxin B1. Carcinogenesis. 17:2347–2356.
   PubMed Web of Science ®Google Scholar
• Eaton DL, Gallagher EP. 1994. Mechanisms of aflatoxin carcinogenesis. Annu Rev Pharmacol Toxicol. 34:135–172.
   PubMed Web of Science ®Google Scholar
• Eaton DL, Schaupp CM. 2014. Of mice, rats, and men: could Nrf2 activation protect against aflatoxin heptocarcinogenesis in humans? Cancer Prev Res (Phila). 7:653–657.
   PubMed Web of Science ®Google Scholar
• Edwards SW, Tan YM, Villeneuve DL, Meek ME, McQueen CA. 2015. Adverse outcome pathways-organizing toxicological information to improve decision making. J Pharmacol Exp Ther. 356:170–181.
   PubMed Web of Science ®Google Scholar
• Egner P, Groopman J, Wang JS, Kensler T, Friesen M. 2006. Quantification of aflatoxin B1 N7 guanine in human urine by LC and isotope dilution tandem mass spectrometry. Chem Res Toxicol. 19:1191–1195.
   PubMed Web of Science ®Google Scholar
• Elegbede AJ, Gould MN. 2002. Monoterpenes reduced adducts formation in rats exposed to aflatoxin B1. Afr J Biotechnol. 1:46–49.
   Google Scholar
• Fabregat I. 2009. Dysregulation of apoptosis in hepatocellular carcinoma cells. World J Gastroenterol. 15:513–520.
   PubMed Web of Science ®Google Scholar
• Farazi PA, DePinho RA. 2006a. The genetic and environmental basis of hepatocellular carcinoma. Discov Med. 6:182–186.
   PubMedGoogle Scholar
• Farazi PA, DePinho RA. 2006b. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 6:674–687.
   PubMed Web of Science ®Google Scholar
• Farazi PA, Glickman J, Jiang S, Yu A, Rudolph KL, DePinho RA. 2003. Differential impact of telomere dysfunction on initiation and progression of hepatocellular carcinoma. Cancer Res. 63:5021–5027.
   PubMed Web of Science ®Google Scholar
• Fay KA, Villeneuve DL, LaLone CA, Song Y, Tollefsen KE, Ankley GT. 2017. Practical approaches to adverse outcome pathway development and weight-of-evidence evaluation as illustrated by ecotoxicological case studies. Environ Toxicol Chem. 36:1429–1449.
   PubMed Web of Science ®Google Scholar
• Fischer G. 1986. Increased UDP-glucuronyltransferase and gamma-glutamyltranspeptidase in enzyme-altered rat liver lesions produced by low doses of aflatoxin B1. Virchows Arch B Cell Pathol. 51:443–460.
   Google Scholar
• Fischer G, Domingo M, Lodder D, Katz N, Reinacher M, Eigenbrodt E. 1987. Immunohistochemical demonstration of decreased L-pyruvate kinase in enzyme altered rat liver lesions produced by different carcinogens. Virchows Arch B Cell Pathol. 53:359–364.
   Google Scholar
• Foster PL, Eisenstadt E, Miller JH. 1983. Base substitution mutations induced by metabolically activated aflatoxin B1. Proc Natl Acad Sci USA. 80:2695–3698.
   PubMed Web of Science ®Google Scholar
• Fransvea E, Angelotti U, Antonaci S, Giannelli G. 2008. Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology. 47:1557–1566.
   PubMed Web of Science ®Google Scholar
• Frith CH, Kodell RL, Littlefield NA. 1980. Biologic and morphologic characteristics of hepatocellular lesions in BALB/c female mice fed 2-acetylaminofluorene. J Environ Pathol Toxicol. 3:121–138.
   PubMed Web of Science ®Google Scholar
• Gil R, Callaghan R, Boix J, Pellin A, Llombart-Bosch A. 1988. Morphometric and cytophotometric nuclear analysis of altered hepatocyte foci induced by N-nitrosomorpholine (NNM) and aflatoxin B1 (AFB1) in liver of Wistar rats. Virchows Arch B Cell Pathol. 54:341–349.
   Google Scholar
• Giri I, Johnston DS, Stone MP. 2002. Mispairing of the 8,9-dihydro-8-(N7-guanyl)-9-hydroxy-aflatoxin B1 adduct with deoxyadenosine results in extrusion of the mismatched dA toward the major groove. Biochemistry. 41:5462–5472.
   PubMed Web of Science ®Google Scholar
• Gocke E, Müller L. 2009. In vivo studies in the mouse to define a threshold for the genotoxicity of EMS and ENU. Mutat Res. 678:101–107.
   PubMed Web of Science ®Google Scholar
• Godlewski CE, Boyd JN, Sherman WK, Anderson JL, Stoewsand GS. 1985. Hepatic glutathione S-transferase activity and aflatoxin B1-induced enzyme altered foci in rats fed fractions of Brussels sprouts. Cancer Lett. 28:151–157.
   PubMed Web of Science ®Google Scholar
• Gold LS, Slone TH, Manley NB, Bernstein L. 1991. Target organs in chronic bioassays of 533 chemical carcinogens. Environ Health Perspect. 93:233–246.
   PubMed Web of Science ®Google Scholar
• Goldfarb S, Pugh TD. 1986. Multistage rodent hepatocarcinogenesis. Prog Liver Dis. 8:597–620.
   PubMedGoogle Scholar
• Goldsworthy TL, Hanigan MH, Pitot HC. 1986. Models of hepatocarcinogenesis in the rat-contrasts and comparisons. Crit Rev Toxicol. 17:61–89.
   PubMed Web of Science ®Google Scholar
• Golubovskaya VM, Filatov LV, Behe CI, Presnell SC, Hooth MJ, Smith GJ, Kaufmann WK. 1999. Telomere shortening, telomerase expression, and chromosome instability in rat hepatic epithelial stem-like cells. Mol Carcinog. 24:209–217.
   PubMed Web of Science ®Google Scholar
• Gong P, Wang Y, Zhang J, Wang Z. 2013. Differential hepatic stem cell proliferation and differentiation after partial hepatectomy in rats. Mol Med Rep. 8:1005–1010.
   PubMed Web of Science ®Google Scholar
• Gouas D, Shi H. 2009. The aflatoxin-induced TP53 mutation at codon 249 (R249S): biomarker of exposure, early detection and target for therapy. Cancer Lett. 286:29–37.
   PubMed Web of Science ®Google Scholar
• Gouas D, Shi H, Hautefeuille A. 2010. Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein. Carcinogenesis. 31:1475–1482.
   PubMed Web of Science ®Google Scholar
• Grasl-Kraupp B, Ruttkay-Nedecky B, Mullauer L, Taper H, Huber W, Bursch W, Schulte-Hermann R. 1997. Inherent increase of apoptosis in liver tumors: implications for carcinogenesis and tumor regression. Hepatology. 25:906–912.
   PubMed Web of Science ®Google Scholar
• Gregory J, Goldstein S, Edds G. 1983. Metabolite distribution and rate of residue clearance in turkeys fed a diet containing aflatoxin B1. Food Chem Toxicol. 21:463–467.
   PubMed Web of Science ®Google Scholar
• Grisham JW. 1996. Interspecies comparison of liver carcinogenesis: implications for cancer risk assessment. Carcinogenesis. 18:59–81.
   Web of Science ®Google Scholar
• Groopman J, Kensler T. 2005. Role of metabolism and viruses in aflatoxin-induced liver cancer. Toxicol Appl Pharmacol. 206:131–137.
   PubMed Web of Science ®Google Scholar
• Gross-Steinmeyer K, Eaton D. 2012. Dietary modulation of the biotransformation and genotoxicity of aflatoxin B(1). Toxicology. 299:69–79.
   PubMed Web of Science ®Google Scholar
• Gross-Steinmeyer K, Stapleton P, Tracy J. 2010. Sulforaphane- and phenethyl isothiocyanate-induced inhibition of aflatoxin B1-mediated genotoxicity in human hepatocytes: role of GSTM1 genotype and CYP3A4 gene expression. Toxicol Sci. 116:422–432.
   PubMed Web of Science ®Google Scholar
• Guengerich F, Johnson W, Ueng Y. 1996. Involvement of cytochrome P450, glutathione S-transferase, and epoxide hydrolase in the metabolism of aflatoxin B1 and relevance to risk of human liver cancer. Environ Health Perspect. 104:557–562.
   PubMed Web of Science ®Google Scholar
• Guo Y, Breeden L, Zarbl H, Preston B. 2005. Expression of a human cytochrome p450 in yeast permits analysis of pathways for response to and repair of aflatoxin-induced DNA damage. Mol Cell Biol. 25:5823–5833.
   PubMed Web of Science ®Google Scholar
• Gursoy-Yuzugullu O, Yuzugullu H, Yilmaz M, Ozturk M. 2011. Aflatoxin genotoxicity is associated with a defective DNA damage response bypassing p53 activation. Liver Int. 31:561–571.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg R. 2000. The hallmarks of cancer. Cell. 100:57–70.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg R. 2011. Hallmarks of cancer: the next generation. Cell. 144:646–674.
   PubMed Web of Science ®Google Scholar
• Hanawalt PC. 2003. Four decades of DNA repair: from early insights to current perspectives. Biochimie. 85:1043–1052.
   PubMed Web of Science ®Google Scholar
• Hanawalt PC, Ford JM, Lloyd DR. 2003. Functional characterization of global genomic DNA repair and its implications for cancer. Mutat Res. 544:107–114.
   PubMed Web of Science ®Google Scholar
• Hang YZ, Hen YC, Hsan HA, Unn RML, Ee PL, Hen CC, Antella RMS. 2003. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation and its relationship to aflatoxin B1-DNA adducts and p53 mutation in hepatocellular carcinoma. Int J Cancer. 103:440–444.
   PubMed Web of Science ®Google Scholar
• Harada T, Maronpot RR, Morris RW, Boorman GA. 1989a. Observations on altered hepatocellular foci in National Toxicology Program two-year carcinogenicity studies in rats. Toxicol Pathol. 17:690–706.
   PubMedGoogle Scholar
• Harada T, Maronpot RR, Morris RW, Stitzel KA, Boorman GA. 1989b. Morphological and stereological characterization of hepatic foci of cellular alteration in control Fischer 344 rats. Toxicol Pathol. 17:579–593.
   PubMedGoogle Scholar
• Haridas V, Hanausek M, Nishimura G. 2004. Triterpenoid electrophiles (avicins) activate the innate stress response by redox regulation of a gene battery. J Clin Invest. 113:65–73.
   PubMed Web of Science ®Google Scholar
• He G, Dhar D, Nakagawa H, Font-Burgada J, Ogata H, Jiang Y, Shalapour S, Seki E, Yost SE, Jepsen K, et al. 2013. Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell. 155:384–396.
   PubMed Web of Science ®Google Scholar
• Hendricks CA, Almeida KH, Stitt MS, Jonnalagadda VS, Rugo RE, Kerrison GF, Engelward BP. 2003. Spontaneous mitotic homologous recombination at an enhanced yellow fluorescent protein (EYFP) cDNA direct repeat in transgenic mice. Proc Natl Acad Sci USA. 100:6325–6330.
   PubMed Web of Science ®Google Scholar
• Hendriks G, Atallah M, Morolli B, Calleja F, Ras-Verloop B, Huijskens I, Raamsman M, van de Water B, Vrieling H. 2012. The ToxTracker assay: novel GFP reporter systems that provide mechanistic insight into the genotoxic properties of chemicals. Toxicol Sci. 125:285–298.
   PubMed Web of Science ®Google Scholar
• Himmelstein M, Boogaard P, Cadet J, Farmer PB, Kim JH, Martin EA, Persaud R, Shuker DE. 2009. Creating context for the use of DNA adduct data in cancer risk assessment: II. Overview of methods of identification and quantitation of DNA damage. Crit Rev Toxicol. 39:679–694.
   PubMed Web of Science ®Google Scholar
• Honda T, Yoshizawa H, Sundararajan C. 2011. Tricyclic compounds containing nonenolizable cyano enones. A novel class of highly potent anti-inflammatory and cytoprotective agents. J Med Chem. 54:1762–1778.
   PubMed Web of Science ®Google Scholar
• Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. 1991. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature. 350:427–428.
   PubMed Web of Science ®Google Scholar
• Huff J, Cirvello J, Haseman J. 1991. Chemicals associated with site-specific neoplasia in 1394 long-term carcinogenesis experiments in laboratory rodents. Environ Health Perspect. 93:247–270.
   PubMed Web of Science ®Google Scholar
• IARC. 1993. IARC monographs on the evaluation of carcinogenic risks to humans. Volume 56: Some naturally occurring substances: food items and constituents, heterocyclic aromatic amines and mycotoxins. [IARC] IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, France: IARC.
   Google Scholar
• Ikeda H, Nishi S, Sakai M. 2004. Transcription factor Nrf2/MafK regulates rat placental glutathione S-transferase gene during hepatocarcinogenesis. Biochem J. 380:515–521.
   PubMed Web of Science ®Google Scholar
• Jackson PE, Kuang SY, Wang JB, Strickland PT, Muñoz A, Kensler TW, Qian GS, Groopman JD. 2003. Prospective detection of codon 249 mutations in plasma of hepatocellular carcinoma patients. Carcinogenesis. 24:1657–1663.
   PubMed Web of Science ®Google Scholar
• Jarabek AM, Pottenger LH, Andrews LS, Casciano D, Embry MR, Kim JH, Preston RJ, Reddy MV, Schoeny R, Shuker D, et al. 2009. Creating context for the use of DNA adduct data in cancer risk assessment: I. Data organization. Crit Rev Toxicol. 39:659–678.
   PubMed Web of Science ®Google Scholar
• Jaramillo M, Zhang D. 2013. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev. 27:2179–2191.
   PubMed Web of Science ®Google Scholar
• Jia S, Ren J, Dong P, Meng X. 2013. Probing the hepatic progenitor cell in human hepatocellular carcinoma. Gastroenterol Res Pract. 2013:145253.
   PubMed Web of Science ®Google Scholar
• Johnson N, Egner P, Baxter V, Sporn M. 2014. Complete protection against aflatoxin B1-induced liver cancer with a triterpenoid: DNA adduct dosimetry, molecular signature, and genotoxicity threshold. Cancer Prev Res (Phila). 7: 658–665.
   Web of Science ®Google Scholar
• Kensler TW, Egner PA, Dolan PM, Groopman JD, Roebuck BD. 1987. Mechanism of protection against aflatoxin tumorigenicity in rats fed 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) and related 1,2-dithiol-3-thiones and 1,2-dithiol-3-ones. Cancer Res. 47:4271–4277.
   PubMed Web of Science ®Google Scholar
• Kensler TW, He X, Otieno M, Egner PA, Jacobson LP, Chen B, Wang JS, Zhu YR, Zhang BC, Wang JB, et al. 1998a. Oltipraz chemoprevention trial in Qidong, People’s Republic of China: modulation of serum aflatoxin albumin adduct biomarkers. Cancer Epidemiol Biomarkers Prev. 7:127–134.
   PubMed Web of Science ®Google Scholar
• Kensler T, Groopman J, Roebuck B. 1998b. Use of aflatoxin adducts as intermediate endpoints to assess the efficacy of chemopreventive interventions in animals and man. Mutat Res. 402:165–172.
   PubMed Web of Science ®Google Scholar
• Kensler TW, Egner PA, Wang JB, Zhu YR, Zhang BC, Lu PX, Chen JG, Qian GS, Kuang SY, Jackson PE, et al. 2004. Chemoprevention of hepatocellular carcinoma in aflatoxin endemic areas. Gastroenterology. 127:S310–S318.
   PubMed Web of Science ®Google Scholar
• Kensler TW, Roebuck BD, Wogan GN, Groopman JD. 2011. Aflatoxin: a 50-year Odyssey of mechanistic and translational toxicology. Toxicol Sci. 120:S28–S48.
   PubMed Web of Science ®Google Scholar
• Kew MC. 2003. Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis. Liver Int. 23:405–409.
   PubMed Web of Science ®Google Scholar
• Kew MC. 2013. Aflatoxins as a cause of hepatocellular carcinoma. J Gastrointestin Liver Dis. 22:305–310.
   PubMed Web of Science ®Google Scholar
• Kimura M, Lehmann K, Gopalan-Kriczky P, Lotlikar PD. 2004. Effect of diet on aflatoxin B1-DNA binding and aflatoxin B1-induced glutathione S-transferase placental form positive hepatic foci in the rat. Exp Mol Med. 36:351–357.
   PubMed Web of Science ®Google Scholar
• Kiraly O, Gong G, Roytman MD, Yamada Y, Samson LD, Engelward BP. 2014. DNA glycosylase activity and cell proliferation are key factors in modulating homologous recombination in vivo. Carcinogenesis. 35:2495–2502.
   PubMed Web of Science ®Google Scholar
• Kiraly O, Gong G, Olipitz W, Muthupalani S, Engelward BP. 2015. Inflammation-induced cell proliferation potentiates DNA damage-induced mutations in vivo. PLoS Genet. 11:e1004901
   PubMed Web of Science ®Google Scholar
• Kirby GM, Stalker M, Metcalfe C, Kocal T, Ferguson H, Hayes MA. 1990. Expression of immunoreactive glutathione S-transferases in hepatic neoplasms induced by aflatoxin B1 or 1,2-dimethylbenzanthracene in rainbow trout (Oncorhynchus mykiss). Carcinogenesis. 11:2255–2257.
   PubMed Web of Science ®Google Scholar
• Kirk GD, Turner PC, Gong Y, Lesi OA, Mendy M, Goedert JJ, Hall AJ, Whittle H, Hainaut P, Montesano R, Wild CP. 2005. Hepatocellular carcinoma and polymorphisms in carcinogen-metabolizing and DNA repair enzymes in a population with aflatoxin exposure and hepatitis B virus endemicity. Cancer Epidemiol Biomarkers Prev. 14:373–379.
   PubMed Web of Science ®Google Scholar
• Kozmin SG, Jinks-Robertson S. 2013. The mechanism of nucleotide excision repair-mediated UV-induced mutagenesis in nonproliferating cells. Genetics. 193:803–817.
   PubMed Web of Science ®Google Scholar
• Kunkel TA. 2004. DNA replication fidelity. J Biol Chem. 279:16895–16898.
   PubMed Web of Science ®Google Scholar
• Kwak MK, Itoh K, Yamamoto M, Sutter TR, Kensler TW. 2001. Role of transcription factor Nrf2 in the induction of hepatic phase 2 and antioxidative enzymes in vivo by the cancer chemoprotective agent, 3H-1, 2-dimethiole-3-thione. Mol Med. 7:135–145.
   PubMed Web of Science ®Google Scholar
• Larsson P, Hoedaya WI, Tjälve H. 1990. Disposition of 3H-aflatoxin B1 in mice: formation and retention of tissue bound metabolites in nasal glands. Pharmacol Toxicol. 67:162–171.
   PubMedGoogle Scholar
• Larsson P, Tjälve H. 1993. Distribution and metabolism of aflatoxin B1 in the marmoset monkey (Callithrix jacchus). Carcinogenesis. 14:1–6.
   PubMed Web of Science ®Google Scholar
• Leadon SA, Tyrrell RM, Cerutti PA. 1981. Excision repair of aflatoxin B1-DNA adducts in human fibroblasts. Cancer Res. 41:5125–5129.
   PubMed Web of Science ®Google Scholar
• Lee YI, Lee S, Das GC, Park US, Park SM, Lee YI. 2000. Activation of the insulin-like growth factor II transcription by aflatoxin B1 induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-of-function during the formation of hepatocellular carcinoma. Oncogene. 19:3717–3726.
   PubMed Web of Science ®Google Scholar
• Leung MCK, Goldstone JV, Boyd WA, Freedman JH, Meyer JN. 2010. Caenorhabditis elegans generates biologically relevant levels of genotoxic metabolites from aflatoxin B1 but not benzo[a]pyrene in vivo. Toxicol Sci. 118:444–453.
   PubMed Web of Science ®Google Scholar
• Levrero M, Zucman-Rossi J. 2016. Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol. 64: S84–S101.
   PubMed Web of Science ®Google Scholar
• Levy DD, Groopman JD, Lim SE, Seidman MM, Kraemer KH. 1992. Sequence specificity of aflatoxin B1-induced mutations in a plasmid replicated in xeroderma pigmentosum and DNA repair proficient human cells. Cancer Res. 52:5668–5673.
   PubMed Web of Science ®Google Scholar
• Liby K, Yore MM, Roebuck BD, Baumgartner KJ, Honda T, Sundararajan C, Yoshizawa H, Gribble GW, Williams CR, Risingsong R, et al. 2008. A novel acetylenic tricyclic bis-(cyano enone) potently induces phase 2 cytoprotective pathways and blocks liver carcinogenesis induced by aflatoxin. Cancer Res. 68:6727–6733.
   PubMed Web of Science ®Google Scholar
• Liby KT, Sporn MB. 2012. Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol Rev. 64:972–1003.
   PubMed Web of Science ®Google Scholar
• Lin YC, Li L, Makarova AV, Burgers PM, Stone MP, Lloyd RS. 2014a. Error-prone replication bypass of the primary aflatoxin B1 DNA adduct, AFB1-N7-Gua. J Biol Chem. 289:18497–18506.
   PubMed Web of Science ®Google Scholar
• Lin YC, Li L, Makarova AV, Burgers PM, Stone MP, Lloyd RS. 2014b. Molecular basis of aflatoxin-induced mutagenesis-role of the aflatoxin B1-formamidopyrimidine adduct. Carcinogenesis. 35:1461–1468.
   PubMed Web of Science ®Google Scholar
• Long X, Ma Y, Deng Z. 2009. GSTM1 and XRCC3 polymorphisms: Effects on levels of aflatoxin B1-DNA adducts. Chin J Cancer Res. 21:177–184.
   Web of Science ®Google Scholar
• Long XD, Ma Y, Qu DY, Liu YG, Huang ZQ, Huang YZ, Lin ZH, Wei NB, Zhou SC. 2008. The polymorphism of XRCC3 codon 241 and AFB1-related hepatocellular carcinoma in Guangxi Population, China. Ann Epidemiol. 18:572–578.
   PubMed Web of Science ®Google Scholar
• Long XD, Ma Y, Wei YP, Deng ZL. 2006. The polymorphisms of GSTM1, GSTT1, HYL1*2, and XRCC1, and aflatoxin B1-related hepatocellular carcinoma in Guangxi population, China. Hepatol Res. 36:48–55.
   PubMed Web of Science ®Google Scholar
• Luo M, Yang F, Huang SX, Kuang ZP, Luo XL, Li YD, Wu JN, Xie YA. 2013. Two-stage model of chemically induced hepatocellular carcinoma in mouse. Oncol Res. 20:517–528.
   PubMed Web of Science ®Google Scholar
• Ma Q, He X. 2012. Molecular basis of electrophilic and oxidative defense: promises and perils of Nrf2. Pharmacol Rev. 64:1055–1081.
   PubMed Web of Science ®Google Scholar
• Macé K, Aguilar F, Wang JS, Vautravers P, Gómez-Lechón M, Gonzalez FJ, Groopman J, Harris CC, Pfeifer AM. 1997. Aflatoxin B1-induced DNA adduct formation and p53 mutations in CYP450-expressing human liver cell lines. Carcinogenesis. 18:1291–1297.
   PubMed Web of Science ®Google Scholar
• Manson MM, Green JA, Neal GE. 1984. Monoclonal antibody against tumour-derived cell line shows heterogeneity of altered hepatocytes during AFB1-induced carcinogenesis. Int J Cancer. 34:869–874.
   PubMed Web of Science ®Google Scholar
• Marchetti F, Massarotti A, Yauk CL, Pacchierotti F, Russo A. 2016. The adverse outcome pathway (AOP) for chemical binding to tubulin in oocytes leading to aneuploid offspring. Environ Mol Mutagen. 57:87–113.
   PubMed Web of Science ®Google Scholar
• Maronpot RR, Harada T, Murthy AS, Boorman GA. 1989. Documenting foci of hepatocellular alteration in two-year carcinogenicity studies: current practices of the National Toxicology Program. Toxicol Pathol. 17:675–683.
   PubMedGoogle Scholar
• Maxuitenko YY, MacMillan DL, Kensler TW, Roebuck BD. 1993. Evaluation of the post-initiation effects of oltipraz on aflatoxin B1-induced preneoplastic foci in a rat model of hepatic tumorigenesis. Carcinogenesis. 14:2423–2425.
   PubMed Web of Science ®Google Scholar
• Meek ME, Boobis A, Cote I, Dellarco V, Fotakis G, Munn S, Seed J, Vickers C. 2014a. New developments in the evolution and application of the WHO/IPCS framework on mode of action/species concordance analysis. J Appl Toxicol. 34:1–18.
   PubMed Web of Science ®Google Scholar
• Meek MEB, Palermo CM, Bachman AN, North CM, Jeffrey Lewis R. 2014b. Mode of action human relevance (species concordance) framework: Evolution of the Bradford Hill considerations and comparative analysis of weight of evidence. J Appl Toxicol. 34:595–606.
   PubMed Web of Science ®Google Scholar
• Meier B, Cooke S, Weiss J, Bailly A. 2014. C. elegans whole-genome sequencing reveals mutational signatures related to carcinogens and DNA repair deficiency. Genome. 24:1624–1636.
   Web of Science ®Google Scholar
• Miura N, Horikawa I, Nishimoto A, Ohmura H. 1997. Progressive telomere shortening and telomerase reactivation during hepatocellular carcinogenesis. Cancer Genet Cytogenet. 93:56–62.
   PubMed Web of Science ®Google Scholar
• Miyajima A, Tanaka M, Itoh T. 2014. Stem/progenitor cells in liver development, homeostasis, regeneration, and reprogramming. Cell Stem Cell. 14:561–574.
   PubMed Web of Science ®Google Scholar
• Monroe D, Eaton D. 1987. Comparative effects of butylated hydroxyanisole on hepatic in vivo DNA binding and in vitro biotransformation of aflatoxin B 1 in the rat and mouse. Toxicol Appl Pharmacol. 14:561–574.
   Google Scholar
• Moore MM, Manjanatha M, Heflich R. 2008. Research strategy to better inform the decision as to whether a carcinogen is a “mutagenic carcinogen,” in: 2008 Meeting of the Society of Toxicology, Baltimore, MD.
   Google Scholar
• Mulder J, Bondy G, Mehta R, Massey T. 2014. Up-regulation of nucleotide excision repair in mouse lung and liver following chronic exposure to aflatoxin B1 and its dependence on p53 genotype. Toxicol Appl Pharmacol. 275:96–103.
   PubMed Web of Science ®Google Scholar
• Newberne PM. 1976. Experimental hepatocellular carcinogenesis. Cancer Res. 36:2573–2578.
   PubMed Web of Science ®Google Scholar
• Nishizumi M, Albert RE, Burns FJ, Bilger L. 1977. Hepatic cell loss and proliferation induced by N-2-fluorenylacetamide, diethylnitrosamine, and aflatoxin B1 in relation to hepatoma induction. Br J Cancer. 36:192–197.
   PubMed Web of Science ®Google Scholar
• O'Dwyer PJ, Johnson SW, Khater C, Krueger A, Matsumoto Y, Hamilton TC, Yao KS. 1997. The chemopreventive agent oltipraz stimulates repair of damaged DNA. Cancer Res. 57:1050–1053.
   PubMed Web of Science ®Google Scholar
• OECD. 2013. Guidance document on developing and assessing adverse outcome pathways. Series on testing and assessment. No. 184. Paris, France: [OECD] Organisation for Economic Co-operation and Development.
   Google Scholar
• OECD. 2014. User’s handbook supplement to the guidance document for developing and assessing AOPs. Paris, France: [OECD] Organisation for Economic Co-operation and Development.
   Google Scholar
• OECD. 2016. Users' Handbook supplement to the Guidance Document for developing and assessing Adverse Outcome Pathways. Paris, France: [OECD] Organisation for Economic Co-operation and Development. Available at: http://www.oecd-ilibrary.org/environment/oecd-series-on-adverse-outcome-pathways_2415170x;jsessionid=20oo8q54271qt.x-oecd-live-03
   Google Scholar
• Olden K, Vulimiri S. 2014. Laboratory to community: chemoprevention is the answer. Cancer Prev Res (Phila). 7:648–652.
   PubMed Web of Science ®Google Scholar
• Oleykowski C, Mayernik J, Lim S. 1993. Repair of aflatoxin B1 DNA adducts by the UvrABC endonuclease of Escherichia coli. J Biol Chem. 268:7990–8002.
   PubMed Web of Science ®Google Scholar
• Palliyaguru D, Wu F. 2013. Global geographical overlap of aflatoxin and hepatitis C: controlling risk factors for liver cancer worldwide. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 30:534–540.
   PubMed Web of Science ®Google Scholar
• Parkin DM, Pisani P, Ferlay J. 1993. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer. 54:594–606.
   PubMed Web of Science ®Google Scholar
• Parsons B, McKinzie P, Heflich R. 2005. Allele-specific competitive blocker-PCR detection of rare base substitution. Mol Toxicol Protoc. 291:235–245.
   Google Scholar
• Parsons B, Myers M, Meng F, Wang Y. 2010. Oncomutations as biomarkers of cancer risk. Environ Mol Mutagen. 51:836–850.
   PubMed Web of Science ®Google Scholar
• Patlewicz G, Simon T, Rowlands J. 2015. Proposing a scientific confidence framework to help support the application of adverse outcome pathways for regulatory purposes. Regul Toxicol Pharmacol. 71:463–477.
   PubMed Web of Science ®Google Scholar
• Perkins EJ, Antczak P, Burgoon L, Falciani F, Garcia-Reyero N, Gutsell S, Hodges G, Kienzler A, Knapen D, McBride M, et al. 2015. Adverse outcome pathways for regulatory applications: examination of four case studies with different degrees of completeness and scientific confidence. Toxicol Sci. 148:14–25.
   PubMed Web of Science ®Google Scholar
• Philippin G, Cadet J, Gasparutto D, Mazon G, Fuchs RP. 2014. Ethylene oxide and propylene oxide derived N7-alkylguanine adducts are bypassed accurately in vivo. DNA Repair (Amst). 22:133–136.
   PubMed Web of Science ®Google Scholar
• Pitot H. 1990. Altered hepatic foci: their role in murine hepatocarcinogenesis. Annu Rev Pharmacol Toxicol. 30:465–500.
   PubMed Web of Science ®Google Scholar
• Pitot HC, Dragan Y, Sargent L, Xu YH. 1991. Biochemical markers associated with the stages of promotion and progression during hepatocarcinogenesis in the rat. Environ Health Perspect. 93:181–189.
   PubMed Web of Science ®Google Scholar
• Pitot HC, Dragan Y, Xu YH, Pyron M, Laufer C, Rizvi T. 1990. Role of altered hepatic foci in the stages of carcinogenesis. Prog Clin Biol Res. 340D:81–95.
   PubMedGoogle Scholar
• Pitot HC, Dragan YP, Teeguarden J, Hsia S, Campbell H. 1996. Quantitation of multistage carcinogenesis in rat liver. Toxicol Pathol. 24:119–128.
   PubMed Web of Science ®Google Scholar
• Pogribny IP, Muskhelishvili L, Tryndyak VP, Beland FA. 2011. The role of epigenetic events in genotoxic hepatocarcinogenesis induced by 2-acetylaminofluorene. Mutat Res Toxicol Environ Mutagen. 722:106–113.
   PubMed Web of Science ®Google Scholar
• Pottenger LH, Andrews LS, Bachman AN, Boogaard PJ, Cadet J, Embry MR, Farmer PB, Himmelstein MW, Jarabek AM, Martin EA, et al. 2014. An organizational approach for the assessment of DNA adduct data in risk assessment: case studies for aflatoxin B1, tamoxifen and vinyl chloride. Crit Rev Toxicol. 44:348–391.
   PubMed Web of Science ®Google Scholar
• Pottenger LH, Gollapudi BB. 2010. Genotoxicity testing: moving beyond qualitative “screen and bin” approach towards characterization of dose-response and thresholds. Environ Mol Mutagen. 51:792–799.
   PubMed Web of Science ®Google Scholar
• Pottenger LH, Schisler MR, Zhang F, Bartels MJ, Fontaine DD, McFadden LG, Bhaskar Gollapudi B. 2009. Dose-response and operational thresholds/NOAELs for in vitro mutagenic effects from DNA-reactive mutagens, MMS and MNU. Mutat Res. 678:138–147.
   PubMed Web of Science ®Google Scholar
• Preston R, Williams G. 2005. DNA-reactive carcinogens: mode of action and human cancer hazard. Crit Rev Toxicol. 35:673–683.
   PubMed Web of Science ®Google Scholar
• Primiano T, Egner P, Sutter T, Kelloff G. 1995. Intermittent dosing with oltipraz: relationship between chemoprevention of aflatoxin-induced tumorigenesis and induction of glutathione S-transferases. Cancer Res. 55:4319–4324.
   PubMed Web of Science ®Google Scholar
• Puisieux A, Lim S, Groopman J, Ozturk M. 1991. Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. Cancer Res. 51:6185–6189.
   PubMed Web of Science ®Google Scholar
• Ribback S, Calvisi D, Cigliano A, Sailer V, Peters M. 2013. Molecular and metabolic changes in human liver clear cell foci resemble the alterations occurring in rat hepatocarcinogenesis. J Hepatol. 58:1147–1156.
   PubMed Web of Science ®Google Scholar
• Roebuck B, Liu Y, Rogers A, Groopman J. 1991. Protection against aflatoxin B1-induced hepatocarcinogenesis in F344 rats by 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione (oltipraz): predictive role for short-term molecular dosimetry. Cancer Res. 51:5501–5506.
   PubMed Web of Science ®Google Scholar
• Russom CL, LaLone CA, Villeneuve DL, Ankley GT. 2014. Development of an adverse outcome pathway for acetylcholinesterase inhibition leading to acute mortality. Environ Toxicol Chem. 33:2157–2169.
   PubMed Web of Science ®Google Scholar
• Sarasin A, Smith C, Hanawalt P. 1977. Repair of DNA in human cells after treatment with activated aflatoxin B1. Cancer Res. 37:1786–1793.
   PubMed Web of Science ®Google Scholar
• Sargent L, Dragan Y, Xu YH, Sattler G, Wiley J, Pitot HC. 1996. Karyotypic changes in a multistage model of chemical hepatocarcinogenesis in the rat. Cancer Res. 56:2985–2991.
   PubMed Web of Science ®Google Scholar
• Sargent L, Xu YH, Sattler GL, Meisner L, Pitot HC. 1989. Ploidy and karyotype of hepatocytes isolated from enzyme-altered foci in two different protocols of multistage hepatocarcinogenesis in the rat. Carcinogenesis. 10:387–391.
   PubMed Web of Science ®Google Scholar
• Sell S. 2003. Mouse models to study the interaction of risk factors for human liver cancer. Cancer Res. 63:7553–7562.
   PubMed Web of Science ®Google Scholar
• Shelton P, Jaiswal A. 2013. The transcription factor NF-E2-related factor 2 (Nrf2): a protooncogene? FASEB J. 27:414–423.
   PubMed Web of Science ®Google Scholar
• Shen H, Ong C. 1996. Mutations of the p53 tumor suppressor gene and ras oncogenes in aflatoxin hepatocarcinogenesis. Mutat Res. 366:23–44.
   PubMed Web of Science ®Google Scholar
• Smela M, Hamm M, Henderson P, Harris CM, Harris TM, Essignmann JM. 2002. The aflatoxin B1 formamidopyrimidine adduct plays a major role in causing the types of mutations observed in human hepatocellular carcinoma. Proc Natl Acad Sci USA. 99:6655–6660.
   PubMed Web of Science ®Google Scholar
• Staib F, Hussain SP, Hofseth L. 2003. TP53 and liver carcinogenesis. Hum Mutat. 21:201–216.
   PubMed Web of Science ®Google Scholar
• Sudakin D. 2003. Dietary aflatoxin exposure and chemoprevention of cancer: a clinical review. J Toxicol Clin Toxicol. 41:195–204.
   PubMed Web of Science ®Google Scholar
• Sukowati CHC, El-Khobar KE, Ie SI, Anfuso B, Muljono DH, Tiribelli C. 2016. Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma. World J Gastroenterol. 22:1497–1512.
   PubMed Web of Science ®Google Scholar
• Swenberg J, Lu K, Moeller B, Gao L. 2010. Endogenous versus exogenous DNA adducts: their role in carcinogenesis, epidemiology and risk assessment. Toxicol Sci. 120:S130–S145.
   PubMed Web of Science ®Google Scholar
• Szymañska K, Chen JG, Cui Y, Gong YY, Turner PC, Villar S, Wild CP, Parkin DM, Hainaut P. 2009. TP53 R249S mutations, exposure to aflatoxin, and occurrence of hepatocellular carcinoma in a cohort of chronic hepatitis B virus carriers from Qidong, China. Cancer Epidemiol Biomarkers Prev. 18:1638–1643.
   PubMed Web of Science ®Google Scholar
• Taguchi K, Takaku M, Egner PA, Morita M, Kaneko T, Mashimo T, Kensler TW, Yamamoto M. 2016. Generation of a new model rat: Nrf2 knockout rats are sensitive to aflatoxin B1 toxicity. Toxicol Sci. 152:40–52.
   PubMed Web of Science ®Google Scholar
• Thoolen B, Ten Kate FJ, van Diest PJ, Malarkey DE, Elmore SA, Maronpot RR. 2012. Comparative histomorphological review of rat and human hepatocellular proliferative lesions. J Toxicol Pathol. 25:189–199.
   PubMed Web of Science ®Google Scholar
• Ueng YF, Shimada T, Yamazaki H, Guengerich FP. 1995. Oxidation of aflatoxin B1 by bacterial recombinant human cytochrome P450 enzymes. Chem Res Toxicol. 8:218–225.
   PubMed Web of Science ®Google Scholar
• Villeneuve DL, Crump D, Garcia-Reyero N, Hecker M, Hutchinson TH, LaLone CA, Landesmann B, Lettieri T, Munn S, Nepelska M, et al. 2014. Adverse outcome pathway (AOP) development I: strategies and principles. Toxicol Sci. 142:312–320.
   PubMed Web of Science ®Google Scholar
• Wang JS, Shen X, He X, Zhu YR, Zhang BC, Wang JB, Qian GS, Kuang SY, Zarba A, Egner PA, et al. 1999. Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of qidong, People's Republic of China. J Natl Cancer Inst. 91:347–354.
   PubMed Web of Science ®Google Scholar
• Wang Y, Meng F, Arlt VM, Mei N, Chen T, Parsons BL. 2011. Aristolochic acid-induced carcinogenesis examined by ACB-PCR quantification of H-Ras and K-Ras mutant fraction. Mutagenesis. 26:619–628.
   PubMed Web of Science ®Google Scholar
• Wattanawaraporn R, Kim MY, Adams J, Trudel LJ, Woo LL, Croy RG, Essigmann JM, Wogan GN. 2012. AFB(1)-induced mutagenesis of the gpt gene in AS52 cells. Environ Mol Mutagen. 53:567–573.
   PubMed Web of Science ®Google Scholar
• Wiktor-Brown DM, Hendricks CA, Olipitz W, Engelwood BP. 2006a. Age-dependent accumulation of recombinant cells in the mouse pancreas revealed by in situ fluorescence imaging. Proc Natl Acad Sci USA. 103:11862–11867.
   PubMed Web of Science ®Google Scholar
• Wiktor-Brown DM, Hendricks CA, Olipitz W, Rogers A, Engelward B. 2006b. Applications of fluorescence for detecting rare sequence rearrangements. In Vivo. Cell Cycle. 5:2715–2719.
   PubMed Web of Science ®Google Scholar
• Wogan GN, Paglialunga S, Newberne PM. 1974. Carcinogenic effects of low dietary levels of aflatoxin B1 in rats. Food Cosmet Toxicol. 12:681–685.
   PubMedGoogle Scholar
• Wu H, Wang Q, Yang H, Tsai W, Chen C. 2013. Global DNA methylation in a population with aflatoxin B1 exposure. Epigenetics. 8:962–969.
   PubMed Web of Science ®Google Scholar
• Wyde M, Cambre T, Lebetkin M, Eldridge S. 2002. Promotion of altered hepatic foci by 2,3,7,8-tetrachlorodibenzo-p-dioxin and 17beta-estradiol in male Sprague-Dawley rats. Toxicol Sci. 68:295–303.
   PubMed Web of Science ®Google Scholar
• Xu YH, Campbell HA, Sattler GL, Hendrich S, Maronpot R, Sato K, Pitot HC. 1990a. Quantitative stereological analysis of the effects of age and sex on multistage hepatocarcinogenesis in the rat by use of four cytochemical markers. Cancer Res. 50:472–479.
   PubMed Web of Science ®Google Scholar
• Xu YH, Maronpot R, Pitot HC. 1990b. Quantitative stereologic study of the effects of varying the time between initiation and promotion on four histochemical markers in rat liver during hepatocarcinogenesis. Carcinogenesis. 11:267–272.
   PubMed Web of Science ®Google Scholar
• Yang L, Ji J. 2014. Transcriptome profiling of malignant transformed rat hepatic stem-like cells by aflatoxin B1. Neoplasma. 61:193–204.
   PubMed Web of Science ®Google Scholar
• Yates MS, Kwak MK, Egner PA, Groopman JD, Bodreddigari S, Sutter TR, Baumgartner KJ, Roebuck BD, Liby KT, Yore MM, et al. 2006. Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole. Cancer Res. 66:2488–2494.
   PubMed Web of Science ®Google Scholar
• Yates MS, Tauchi M, Katsuoka F, Flanders KC, Liby KT, Honda T, Gribble GW, Johnson DA, Johnson JA, Burton NC, et al. 2007. Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Mol Cancer Ther. 6:154–162.
   PubMed Web of Science ®Google Scholar
• Yauk CL, Bishop J, Dearfield KL, Douglas GR, Hales BF, Luijten M, O’Brien JM, Robaire B, Sram R, van Benthem J, et al. 2013. The development of adverse outcome pathways for mutagenic effects for the organization for economic co-operation and development. Environ Mol Mutagen. 54:79–81.
   PubMed Web of Science ®Google Scholar
• Yauk CL, Lambert IB, Meek MEB, Douglas GR, Marchetti F. 2015. Development of the adverse outcome pathway “alkylation of DNA in male premeiotic germ cells leading to heritable mutations” using the OECD’s users’ handbook supplement. Environ Mol Mutagen. 56:724–750.
   PubMed Web of Science ®Google Scholar
• Youngman LD, Campbell TC. 1992a. Inhibition of aflatoxin B1-induced gamma-glutamyltranspeptidase positive (GGT+) hepatic preneoplastic foci and tumors by low protein diets: evidence that altered GGT + foci indicate neoplastic potential. Carcinogenesis. 13:1607–1613.
   PubMed Web of Science ®Google Scholar
• Youngman LD, Campbell TC. 1992b. Attenuation of preneoplastic lesion development by dietary protein intervention: apparent persistence and regression. Cancer Lett. 66:165–174.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen Y, Ahsan H, Lunn R. 2003. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation and its relationship to aflatoxin B1-DNA adducts and p53 mutation in hepatocellular carcinoma. Int J Cancer. 103:440–444.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Rossner P, Chen Y. 2006. Aflatoxin B1 and polycyclic aromatic hydrocarbon adducts, p53 mutations and p16 methylation in liver tissue and plasma of hepatocellular carcinoma patients. Int J Cancer. 119:985–991.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wu H, Yazici H, Yu M, Lee P, Santella RM. 2012. Global hypomethylation in hepatocellular carcinoma and its relationship to aflatoxin B(1) exposure. World J Hepatol. 4:169–175.
   PubMedGoogle Scholar
• Zhu H, Wu J, Shen X. 2017. Genome-wide association study: new genetic insights into HBV/HCV-related hepatocellular carcinoma genomes. Scand J Gastroenterol. 52:209–215.
   PubMed Web of Science ®Google Scholar